Search results

Order by most recent / most popular / relevance

Results: 1-10 of 752

Pharma in brief - Canada: Federal Court dismisses prohibition application for drospirenone YASMIN due to non-infringing process

Norton Rose Canada LLP
-
Canada
-
June 15 2013

Bayer Inc. and Bayer Pharma Aktiengesellschaft (“Bayer”) brought an application pursuant to section 6 of the Patented Medicines (Notice of

Guidelines on medical uses released by the Patent Office

Marks & Clerk LLP
-
Canada
-
June 13 2013

On June 10, 2013, the Canadian Intellectual Property Office (CIPO) released examination guidelines on medical use claims. In particular, the

US Supreme Court releases Myriad, isolated DNA unpatentable what it means for Canada

Smart & Biggar/Fetherstonhaugh
-
Canada, USA
-
June 13 2013

The Supreme Court of the United States today issued its opinion in Association for Molecular Pathology et al. v. Myriad Genetics, Inc. et al., 569 U

IP monitor - highway to be built between Canada and China

Norton Rose Canada LLP
-
Canada, China
-
June 12 2013

On May 31, 2013 the Canadian Intellectual Property Office ("CIPO") and the State Intellectual Property Office ("SIPO") of the People's Republic of

White House pushes for innovation in U.S. patent system

Stikeman Elliott LLP
-
Canada, USA
-
June 12 2013

On June 4, 2013, the President of the United States announced seven legislative recommendations to Congress and five executive actions designed to

After reconsideration, the Viagra patent is not void

Fasken Martineau DuMoulin LLP
-
Canada
-
June 11 2013

Close to seven months after rendering its decision in Teva Canada Ltd v Pfizer Canada Inc., 2012 SCC 60, the Supreme Court of Canada varied its

Intellectual property weekly abstracts bulletin

Borden Ladner Gervais LLP
-
Canada
-
June 10 2013

In November, the Supreme Court issued its decision in the sildenafil case, and, as part of its order, found the patent to be invalid. As this case was

CIPO issues guidelines concerning examination of patent claims relating to medical uses

Smart & Biggar/Fetherstonhaugh
-
Canada
-
June 10 2013

The Canadian Intellectual Property Office (CIPO) has today issued guidelines concerning the examination of patent claims relating to medical uses

The process is an essential element of a product-by-process claim

SIM. IP Practice
-
Canada
-
June 7 2013

Bayer attempted to broaden the scope of a product-by-process claim by arguing that the process recited in the claim was a non-essential feature and

Supreme Court varies VIAGRA ruling, confirms that patent is neither invalid nor void

Smart & Biggar/Fetherstonhaugh
-
Canada
-
June 6 2013

The Supreme Court of Canada has clarified its ruling in Teva Canada Ltd v Pfizer Canada Inc, 2012 SCC 60. The Court has confirmed that the patent in

next >

Search results

Pharma in brief - Canada: Federal Court dismisses prohibition application for drospirenone YASMIN due to non-infringing process

Guidelines on medical uses released by the Patent Office

US Supreme Court releases Myriad, isolated DNA unpatentable what it means for Canada

IP monitor - highway to be built between Canada and China

White House pushes for innovation in U.S. patent system

After reconsideration, the Viagra patent is not void

Intellectual property weekly abstracts bulletin

CIPO issues guidelines concerning examination of patent claims relating to medical uses

The process is an essential element of a product-by-process claim

Supreme Court varies VIAGRA ruling, confirms that patent is neither invalid nor void

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea